Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

Journal of Neurochemistry

Volumn 103, Issue 2, 2007, Pages 500-508

  Bar Am, Orit ^b   Amit, Tamar ^b   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NONE

Author keywords

Aminonidan; Apoptosis; Bcl 2 family; Hydroxyaminoindan; Ladostigil; Metabolites; Neuroprotection; Parkinson's disease; Protein kinase C; Rasagiline

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AMINOINDAN; CASPASE 3; CASPASE 9; CHOLINESTERASE; DRUG METABOLITE; HYDROXYAMINOINDAN; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; OXIDOPAMINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE C INHIBITOR; RASAGILINE; SERINE; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; HUMANS; INDANS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PC12 CELLS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SYMPATHOLYTICS; TETRAZOLIUM SALTS; THIAZOLES;

RATTUS;

EID: 34848906324     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04777.x     Document Type: Article

References (55)

1. Abu-Raya S., Tabakman R., Blaugrund E., Trembovler V. Lazarovici P. (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434, 109 116.
2. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M. B. H., Tsujimoto Y. Naoi M. (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J. Neurochem. 82, 913 923.
3. Andoh T., Lee S. Y. Chiueh C. C. (2000) Preconditioning regulation of bcl-2 and p66shc by human NOS1 enhances tolerance to oxidative stress. FASEB J. 14, 2144 2146.
4. Ba F., Pang P. K. T. Benishin C. G. (2003) The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture. J. Neurosci. Methods 123, 11 22.
5. Bar-Am O., Amit T. Youdim M. B. H (2004a) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169 172.
6. Bar-Am O., Yogev-Falach M., Amit T., Sagi Y. Youdim M. B. H. (2004b) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 89, 1119 1125.
7. Bar-Am O., Weinreb O., Amit T. Youdim M. B. (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19, 1899 1901.
8. Biedler J. L., Roffler-Tarlov S., Schachner M. Freedman L. S. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38, 3751 3757.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135 172.
10. Bove J., Prou D., Perier C. Przedborski S. (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2, 484 494.
11. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248 254.
12. Buccafusco J. J., Terry A. V. Jr., Goren T. Blaugrun E. (2003) Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 119, 669 678.
13. Checkoway H., Powers K., Smith-Weller T., Franklin G. M., Longstreth W. T. Jr. Swanson P. D. (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155, 732 738.
14. Durkin J. P., Tremblay R., Chakravarthy B., Mealing G., Morley P., Small D. Song D. (1997) Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J. Neurochem. 68, 1400 1412.
15. Elkon H., Melamed E. Offen D. (2004) Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 24, 387 400.
16. Eminel S., Klettner A., Roemer L., Herdegen T. Waetzig V. (2004) JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine. J. Biol. Chem. 279, 55385 55392.
17. Gekeler V., Boer R., Uberall F. et al. (1996) Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br. J. Cancer 74, 897 905.
18. Glezer S. Finberg J. P. (2003) Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur. J. Pharmacol. 472, 173 177.
19. Guay D. R. (2006) Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am. J. Geriatr. Pharmacother. 4, 330 346.
20. Gubina E., Rinaudo M. S., Szallasi Z., Blumberg P. M. Mufson R. A. (1998) Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood 91, 823 829.
21. Hanrott K., Gudmunsen L., O'Neill M. J. Wonnacott S. (2006) 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281, 5373 5382.
22. Kao T. K., Ou Y. C., Kuo J. S., Chen W. Y., Liao S. L., Wu C. W., Chen C. J., Ling N. N., Zhang Y. H. Peng W. H. (2006) Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats. Neurochem. Int. 48, 166 176.
23. Kim R 2005) Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem. Biophys. Res. Commun. 333, 336 343.
24. Ku W. C., Cheng A. J. Wang T. C. (1997) Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. 241, 730 736.
25. Maher P. (2001) How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21, 2929 2938.
26. Maruyama W., Akao Y., Youdim M. B. H. Naoi M. (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. 60 (Suppl. 171 186.
27. Maruyama W., Weinstock M., Youdim M. B., Nagai M. Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase- monoamine oxidase inhibitor. Neurosci. Lett. 341, 233 236.
28. Ochu E. E., Rothwell N. J. Waters C. M. (1998) Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J. Neurochem. 70, 2637 2640.
29. Paull T. T., Rogakou E. P., Yamazaki V., Kirchgessner C. U., Gellert M. Bonner W. M. (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10, 886 895.
30. Poltyrev T., Gorodetsky E., Bejar C., Schorer-Apelbaum D. Weinstock M. (2005) Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology (Berl.) 181, 118 125.
31. Robertson J. D. Orrenius S. (2000) Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit. Rev. Toxicol. 30, 609 627.
32. Ruvolo P. P., Deng X., Carr B. K. May W. S. (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273, 25436 25442.
33. Sai K., Yang D., Yamamoto H., Fujikawa H., Yamamoto S., Nagata T., Saito M., Yamamura T. Nishizaki T. (2006) A1 adenosine receptor signal and AMPK involving caspase-9/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma cell death. Neurotoxicology 27, 458-467.
34. Shoham S., Bejar C., Kovalev E., Schorer-Apelbaum D. Weinstock M. (2007) Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52, 836 843.
35. Speiser Z., Levy R. Cohen S. (1998) Effects of N-propargyl-1-(R) aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural Transm. (Suppl.) 52, 287 300.
36. Sterling J., Herzig Y., Goren T. et al. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45, 5260 5279.
37. Tatton W. G., Ju W. Y., Holland D. P., Tai C. Kwan M. (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572 1575.
38. Tsujimoto Y. Shimizu S. (2000) Bcl-2 family: life-or-death switch. FEBS Lett. 466, 6 10.
39. Wadia J. S., Chalmers-Redman R. M. E., Ju W. J. H., Carlile G. W., Phillips J. L., Fraser A. D. Tatton W. G. (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18, 932 947.
40. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O. Youdim M. B. H. (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18, 1471 1473.
41. Weinstock M., Goren T. Youdim M. B. H. (2000a) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. 50, 216 222.
42. Weinstock M., Bejar C., Wang R. H., Poltyrev T., Gross A., Finberg J. Youdim M. B. H. (2000b) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. (Suppl.) 60, S157 S170.
43. Xu R., Liu J., Chen X., Xu F., Xie Q., Yu H., Guo Q., Zhou X. Jin Y. (2001) Ribozyme-mediated inhibition of caspase-3 activity reduces apoptosis induced by 6-hydroxydopamine in PC12 cells. Brain Res. 899, 10 19.
44. Yang L., He H. Y. Zhang X. J. (2002) Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells. Neurosci. Res. 42, 261 268.
45. Yogev-Falach M., Amit T., Bar-Am O., Sagi Y., Weinstock M. Youdim M. B. H. (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16, 1674 1676.
46. Yogev-Falach M., Amit T., Bar-AM O. Youdim M. B. H. (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J. 17, 2325 2327.
47. Yogev-Falach M., Bar-Am O., Amit T., Weinreb O. Youdim M. B. (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20 (12 2177 2179.
48. Youdim M. B. Bakhle Y. S. (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 147 (Suppl. 1 S287 S296.
49. Youdim M. B. H. Weinstock M. (2002a) Molecular basis of neuroprotective activities of rasagiline and the anti Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 21, 555 573.
50. Youdim M. B. H. Weinstock M. (2002b) Novel Neuroprotective anti-Alzheimer drugs with antidepressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Ageing Dev. 123, 1081 1086.
51. Youdim M. B. H., Grunblatt E., Levites Y. Mandel S., eds (2001a) Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Adv. Neurol. 86, 115 124. Lippincott Williams & Wilkins, Philadelphia, PA.
52. Youdim M. B. H., Wadia A., Tatton N. A. Weinstock M. (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450 458.
53. Zheng H., Gal S., Weiner L. M., Bar-Am O., Warshawsky A., Fridkin M. Youdim M. B. (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95, 68 78.
54. Zimmermann K., Roggo S., Kragten E., Furst P. Waldmeier P. (1998) Synthesis of tools for target identification of the anti-apoptotic compound CGP 3466; Part I. Bioorg. Med. Chem. Lett. 8, 1195 1200.
55. Zou H., Li Y., Liu X. Wang X. (1999) An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549 11556.